Physician profile
James E Lingeman
NPI 1316947096
$9,932.31
in general payments reported to CMS, 2019-2025
9 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,257 · 2020: $79.83 · 2022: $4,488 · 2023: $342 · 2024: $481 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,753.35 | 2019-2025 | Lithovue, Flexiva, Ams 700 |
| Alnylam Pharmaceuticals INC. | $3,475.00 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $200.64 | 2024-2025 | Bard Urinary Drainage Bag |
| Medical Device Business Services, INC. | $149.79 | 2024 | |
| Richard Wolf Medical Instruments Corp. | $117.14 | 2022 | |
| Ambu INC. | $115.34 | 2024 | |
| Astellas Pharma US INC | $82.65 | 2022 | |
| Calyxo, INC. | $38.40 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lingeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.